AtriCure Inc.
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
AtriCure, Inc. creates, produces, and markets medical devices for the surgical treatment of cardiac tissue and intercostal nerves. Its market reach spans the United States, Europe, Asia, and other int...
Latest News
20 days ago · businesswire.com
AtriCure to Announce Third Quarter 2026 Financial ResultsMASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2026 financial results on Tuesday, November 3, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, November 3, 2026, to discuss its third quarter financial results. Those interested in liste.
2 months ago · zacks.com
Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
2 months ago · zacks.com
Do Options Traders Know Something About AtriCure Stock We Don't?Investors need to pay close attention to ATRC stock based on the movements in the options market lately.
2 months ago · zacks.com
AtriCure, Inc. (ATRC) Hit a 52 Week High, Can the Run Continue?AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
2 months ago · zacks.com
Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.
2 months ago · seekingalpha.com
AtriCure: Promising Cardiovascular Surgical PlatformAtriCure is building a broader surgical platform across appendage management, ablation, and postoperative pain care. They have AtriClip, EnCompass, and cryoSPHERE. These products give them a diversified revenue base. However, we've already seen that catheter-based PFA competition could certainly pressure their growth and margin potential, which is a risk worth considering.
3 months ago · marketbeat.com
AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel GrowthAtriCure NASDAQ: ATRC said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials.
3 months ago · gurufocus.com
A Look at AtriCure Inc (ATRC) After 3.1% Gain -- GF Value $39.42 vs Price $42.95On August 11, 2026, AtriCure Inc (ATRC) shares rose 3.1% to a current price of $42.95, maintaining a strong performance in the market. Over the past week, the s
3 months ago · fool.com
Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for InvestorsThis disposition involved 3,500 shares at $38.42 per share, totaling $134,470. The transaction reduced the director's total equity holdings by 20%, based on holdings reported in the Form 4.
3 months ago · fool.com
An AtriCure Director Sold $905,000 in Stock. Here's How to Read ItKaren Prange disposed of 3,564 shares for a total transaction value of approximately $138,283 on August 5. The sale resulted in a 14% reduction in the director's total direct equity holdings in the company.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ATRC